Some high blood pressure drugs may be associated with increased risk of vision-threatening disease

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

AMD – the deterioration of the eye's macula, which is responsible for the ability to see fine details clearly – affects an estimated 11 million people in the United States. In addition to increased age, the cause of AMD may be attributed to several risk factors, including hereditary risk and smoking. Some studies have also found an association between AMD and , but this has been inconsistent. To help clarify the relationship between AMD incidence and blood pressure lowering medications, including vasodilators, researchers from the University of Wisconsin School of Medicine and Public Health conducted a long-term population-based cohort study from 1988 to 2013 of nearly 5,000 residents of Beaver Dam, Wis., aged 43 to 86 years. The research is part of the National Eye Institute -funded Beaver Dam Eye Study, which has since 1987 collected information on the prevalence and incidence of AMD, and diabetic retinopathy.

The researchers found that, after adjusting for age, sex and other factors, using any vasodilator such as Apresoline and Loniten, which open (dilate) the blood vessels – was associated with a 72 percent greater risk of developing early-stage AMD. Among people who were not taking vasodilators, an estimated 8.2 percent developed signs of early AMD. In comparison, among those taking a vasodilator medication, 19.1 percent developed the disease.

The researchers also found that taking oral beta blockers such as Tenormin and Lopressor was associated with a 71 percent increase in the risk of neovascular AMD, a more advanced and vision-threatening form of the disease. Among those who were not taking oral beta blockers an estimated 0.5 percent developed signs of neovascular AMD. In comparison among those taking oral beta blockers, 1.2 percent developed neovascular AMD.

While the study provides risk estimates of associations between lowering medications and AMD at various stages, the researchers caution that their study was not able to discern effects of the medications themselves and the conditions for which participants were taking those medications.

"As significant as these results may be, it's important that they be replicated first, and if possible tested in a clinical trials setting before changing anyone's medication regimens," said Ronald Klein, M.D., MPH, lead researcher of the study. "Further research is needed to determine the cause of these increased risks."

Related Stories

Genotyping IDs long-term risk of macular degeneration

date Nov 13, 2012

(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing ...

Patients with AMD may not need monthly injections

date May 06, 2014

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary. The research is being presented at the 2014 Annual Meeting ...

Findings support link between hsCRP, macular degeneration

date Feb 08, 2013

(HealthDay)—Pooled results from five cohorts confirm that high levels of high-sensitivity C-reactive protein (hsCRP) correlate with increased future risk of age-related macular degeneration (AMD), according ...

Recommended for you

Miniature pump regulates internal ocular pressure

date Jul 01, 2015

Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing ...

Closing the Australian eye health gap may be in sight

date Jun 30, 2015

Three years after the launch of the roadmap to close the gap for vision, progress has been made but "much remains to be done", according to the authors of a Perspective published online today by the Medical Jo ...

Pioneering gene therapy takes aim at inherited blindness

date Jun 29, 2015

Canada's first human gene therapy trial for eyes—the replacement of a faulty gene with a healthy one—is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people ...

Iris research focuses on blood vessel patterns

date Jun 29, 2015

The structure of the microvasculature or blood vessels in the iris could play an important role in people's contraction of eye maladies like glaucoma and cataract, according to a WA-led study.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.